Search

Your search keyword '"Muffly, Lori S."' showing total 16 results
Start Over Author "Muffly, Lori S." Publication Year Range This year
16 results on '"Muffly, Lori S."'

1. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD

Author

Bader, Cameron S., Pavlova, Anna, Lowsky, Robert, Muffly, Lori S., Shiraz, Parveen, Arai, Sally, Johnston, Laura J., Rezvani, Andrew R., Weng, Wen-Kai, Miklos, David B., Frank, Matthew J., Tamaresis, John S., Agrawal, Vaibhav, Bharadwaj, Sushma, Sidana, Surbhi, Shizuru, Judith A., Fernhoff, Nathaniel B., Putnam, Amy, Killian, Scott, Xie, Bryan J., Negrin, Robert S., and Meyer, Everett H.

Published
2024
Full Text
View/download PDF

2. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

Author

Aldoss, Ibrahim, Roloff, Gregory W., Faramand, Rawan, Kopmar, Noam E., Lin, Chenyu, Advani, Anjali S., Dekker, Simone E., Gupta, Vishal K., O'Connor, Timothy E., Jeyakumar, Nikeshan, Muhsen, Ibrahim N., Valtis, Yannis, Zhang, Amy, Miller, Katharine, Sutherland, Katherine, Dykes, Kaitlyn C., Ahmed, Mohamed, Chen, Evan, Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul, Logan, Aaron C., Ladha, Abdullah, Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, Connor, Matthew, O'Dwyer, Kristen M., Hill, LaQuisa C., Tsai, Stephanie B., Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian, Leonard, Jessica T., Frey, Noelle V., Park, Jae H., Luskin, Marlise R., Bachanova, Veronika, Galal, Ahmed, Bishop, Michael R., Stock, Wendy, Cassaday, Ryan D., Pullarkat, Vinod, Shah, Bijal D., and Muffly, Lori S.

Published
2024
Full Text
View/download PDF

3. Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.

Author

Sidana, Surbhi, Bankova, Andriyana K., Hosoya, Hitomi, Kumar, Shaji K., Holmes, Tyson H., Tamaresis, John, Le, Anne, Muffly, Lori S., Maysel-Auslender, Sofia, Johnston, Laura, Arai, Sally, Lowsky, Robert, Meyer, Everett, Rezvani, Andrew, Weng, Wen-Kai, Frank, Matthew J., Shiraz, Parveen, Maecker, Holden T., Lu, Ying, and Miklos, David B.

Subjects
HEMATOPOIETIC stem cells, MULTIPLE myeloma, CD34 antigen, STEM cells, FLOW cytometry
Abstract

MGTA-145 or GROβT, a CXCR2 agonist, has shown promising activity for hematopoietic stem cell (HSC) mobilization with plerixafor in pre-clinical studies and healthy volunteers. Twenty-five patients with multiple myeloma enrolled in a phase 2 trial evaluating MGTA-145 and plerixafor for HSC mobilization (NCT04552743). Plerixafor was given subcutaneously followed 2 h later by MGTA-145 (0.03 mg/kg) intravenously with same day apheresis. Mobilization/apheresis could be repeated for a second day in patients who collected <6 ×106 CD34+ cells/kg. Lenalidomide and anti-CD38 antibody were part of induction therapy in 92% (n = 23) and 24% (n = 6) of patients, respectively. Median total HSC cell yield (CD34+ cells/kg × 106) was 5.0 (range: 1.1–16.2) and day 1 yield was 3.4 (range: 0.3–16.2). 88% (n = 22) of patients met the primary endpoint of collecting 2 ×106 CD34+ cells/kg in ≤ two days, 68% (n = 17) in one day. Secondary endpoints of collecting 4 and 6 × 106 CD34+ cells/kg in ≤ two days were met in 68% (n = 17) and 40% (n = 10) patients. Grade 1 or 2 adverse events (AE) were seen in 60% of patients, the most common AE being grade 1 pain, usually self-limited. All 19 patients who underwent transplant with MGTA-145 and plerixafor mobilized HSCs engrafted successfully, with durable engraftment at day 100. 74% (17 of 23) of grafts with this regimen were minimal residual disease negative by next generation flow cytometry. Graft composition for HSCs and immune cells were similar to a contemporaneous cohort mobilized with G-CSF and plerixafor. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Predicting relapse in acute lymphoblastic leukemia.

Author

Schwartz, Marc S. and Muffly, Lori S.

Subjects
*LYMPHOBLASTIC leukemia, *ANTIGEN receptors, *CHILD patients, *STEM cell transplantation, *ACUTE leukemia
Abstract

AbstractOutcomes in adult and pediatric patients with acute lymphoblastic leukemia (ALL) have improved over successive generations due to rigorously conducted clinical trials and incorporation of novel therapeutic agents. Despite these advances, approximately 20% of high-risk pediatric patients and 50% of adults with ALL will fail to achieve long-term remission with frontline chemotherapy protocols, mostly due to relapse. The ability to predict which patients with ALL are more likely to relapse allows for early intensification of therapy and/or incorporation of novel immunotherapies with the goal of relapse prevention. In this review, we outline the most robust clinical predictors of relapse in ALL with a focus on measurable residual disease (MRD) and genomics. We also discuss application of these prognostic tools in different clinical settings including frontline treatment, pre-/post-allogeneic stem cell transplant, and pre-/post-Chimeric Antigen Receptor T-cell therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Travel-time barriers to specialized cancer care for adolescents and young adults with acute lymphoblastic leukemia.

Author

Parsons, Helen M, Muffly, Lori S, Garcia, Ariadna, Zhang, Amy, Miller, Kate, Riper, David Van, Knowles, Kate, and Keegan, Theresa H

Subjects
YOUNG adults, LYMPHOBLASTIC leukemia, CANCER treatment, MEDICALLY underserved areas, ACUTE leukemia, SPECIALTY hospitals
Abstract

Background Prior studies demonstrate that 20%-50% of adolescents and young adults (age 15-39 years) with acute lymphoblastic leukemia (ALL) receive care at specialty cancer centers, yet a survival benefit has been observed for patients at these sites. Our objective was to identify patients at risk of severe geographic barriers to specialty cancer center–level care. Methods We used data from the North American Association of Central Cancer Registries Cancer in North America database to identify adolescent and young adult ALL patients diagnosed between 2004 and 2016 across 43 US states. We calculated driving distance and travel time from counties where participants lived to the closest specialty cancer center sites. We then used multivariable logistic regression models to examine the relationship between sociodemographic characteristics of counties where adolescent and young adult ALL patients resided and the need to travel more than 1 hour to obtain care at a specialty cancer center. Results Among 11 813 adolescent and young adult ALL patients, 43.4% were aged 25-39 years, 65.5% were male, 32.9% were Hispanic, and 28.7% had public insurance. We found 23.6% of adolescent and young adult ALL patients from 60.8% of included US counties would be required to travel more than 1 hour one way to access a specialty cancer center. Multivariable models demonstrate that patients living in counties that are nonmetropolitan, with lower levels of educational attainment, with higher income inequality, with lower internet access, located in primary care physician shortage areas, and with fewer hospitals providing chemotherapy services are more likely to travel more than 1 hour to access a specialty cancer center. Conclusions Substantial travel-related barriers exist to accessing care at specialty cancer centers across the United States, particularly for patients living in areas with greater concentrations of historically marginalized communities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Author

Lin, Chenyu, primary, Tsai, Dr. Stephanie B., additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Kopmar, Noam E., additional, Dekker, Simone E., additional, Jeyakumar, Nikeshan, additional, Gupta, Vishal, additional, O'Connor, Timothy E, additional, Dykes, Kaitlyn C, additional, Ahmed, Mohamed, additional, Dholaria, Dr. Bhagirathbhai, additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Logan, Aaron C., additional, Tracy, Sean, additional, Kubiak, Michal, additional, Solh, Melhem M, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Mukherjee, Akash, additional, Battiwalla, Minoo, additional, Shaughnessy, Paul J., additional, Majhail, Navneet S., additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Ladha, Dr. Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Lee, Catherine J, additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Shah, Bijal D., additional, and Faramand, Rawan G, additional

Published
2024
Full Text
View/download PDF

7. CD22 CAR T-Cells Manufactured in Prodigy System and in Bag Culture Yield Equivalent Responses for B-ALL

Author

Dreyzin, Alexandra, primary, Kramer, Anne Marijn, additional, Yates, Bonnie, additional, Wang, Hao-Wei, additional, Sahaf, Bita, additional, Yuan, Constance, additional, Ehlinger, Zachary, additional, Patil, Sunita, additional, Martin, Kathryn, additional, Muffly, Lori S, additional, Shalabi, Haneen, additional, Davis, Kara L, additional, Frank, Matthew J., additional, Schultz, Liora Michal, additional, Altan-Bonnet, Gregoire, additional, Mackall, Crystal L., additional, Taylor, Naomi, additional, Highfill, Steven, additional, Feldman, Steven, additional, Stroncek, David F., additional, Ramakrishna, Sneha, additional, and Shah, Nirali N., additional

Published
2024
Full Text
View/download PDF

8. CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Author

Hamilton, Mark P., primary, Sworder, Brian, additional, Alig, Stefan, additional, Good, Zinaida, additional, Boegeholz, Jan, additional, Schroers-Martin, Joseph, additional, Tamaresis, John, additional, Esfahani, Mohammad, additional, Lu, Ying, additional, Olsen, Mari, additional, Liu, Chih Long, additional, Ehlinger, Zachary, additional, Desai, Moksha, additional, Liu-Fei, Felicia, additional, Muffly, Lori S, additional, Negrin, Robert S., additional, Arai, Sally, additional, Johnston, Laura, additional, Lowsky, Robert, additional, Meyer, Everett H., additional, Rezvani, Andrew R., additional, Shizuru, Judith A., additional, Weng, Wen-Kai, additional, Shiraz, Parveen, additional, Sidana, Surbhi, additional, Bharadwaj, Sushma, additional, Smith, Melody, additional, Dahiya, Saurabh, additional, Sahaf, Bita, additional, Diehn, Max, additional, Frank, Matthew J., additional, Mackall, Crystal L., additional, Kurtz, David, additional, Miklos, David B., additional, and Alizadeh, Ash A., additional

Published
2024
Full Text
View/download PDF

9. Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care

Author

Muhsen, Ibrahim N., primary, Roloff, Gregory, additional, Kopmar, Noam E., additional, Mercadal, Santiago, additional, O'Connor, Timothy E, additional, Dykes, Kaitlyn C, additional, Ahmed, Mohamed, additional, Dekker, Simone E., additional, Jeyakumar, Nikeshan, additional, Veeraputhiran, Muthu, additional, Mukherjee, Akash, additional, Logan, Aaron C., additional, Tsai, Dr. Stephanie B., additional, Leonard, Jessica T., additional, Schwartz, Marc, additional, Sasine, Joshua P, additional, Cassaday, Ryan D., additional, Shah, Bijal D., additional, Muffly, Lori S, additional, Hill, LaQuisa Chimere, additional, and Aldoss, Ibrahim, additional

Published
2024
Full Text
View/download PDF

10. Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Author

Oliai, Caspian, primary, Pantin, Jeremy, additional, Hoeg, Rasmus T, additional, Muffly, Lori S, additional, Patel, Sagar S., additional, Gandhi, Arpita, additional, Lowsky, Robert, additional, Salhotra, Amandeep, additional, Dholaria, Dr. Bhagirathbhai, additional, Waller, Edmund K., additional, SrourChB, Samer A.MB, additional, Pavlova, Anna, additional, Fernhoff, Nathaniel B., additional, Agodoa, Irene, additional, McClellan, James Scott, additional, Abedi, Mehrdad, additional, Negrin, Robert S., additional, and Meyer, Everett H., additional

Published
2024
Full Text
View/download PDF

11. Age-Related Differences in Utilization of Allogeneic HCT for Acute Myeloid Leukemia in California: Results of a Population-Based, Novel Linked Dataset

Author

Meyer, Christa L., primary, Keegan, Theresa H.M., additional, Brunson, Ann, additional, Auletta, Jeffery J., additional, Morton, Lindsay M., additional, Wun, Ted, additional, Schonfeld, Sara J, additional, Valcarcel, Bryan, additional, Abrahao, Renata, additional, Yusuf, Rafeek A., additional, and Muffly, Lori S, additional

Published
2024
Full Text
View/download PDF

12. Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy

Author

Lust, Hannah, primary, Roloff, Gregory, additional, Schultz, Liora Michal, additional, Muffly, Lori S, additional, Krugman, Jessica, additional, Aldoss, Ibrahim, additional, Kwon, Soyang, additional, Kubiak, Michal, additional, Lee, Catherine J., additional, Cassaday, Ryan D., additional, Shah, Bijal D., additional, Baggott, Christina, additional, Kopmar, Noam E., additional, Bradshaw, Danielle, additional, Schwartz, Marc, additional, Tracy, Sean, additional, Mukherjee, Akash, additional, Ladha, Abdullah, additional, Yaghmour, George, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Kota, Vamsi, additional, Veeraputhiran, Muthu, additional, Stock, Wendy, additional, Rossoff, Jenna, additional, Qayed, Muna, additional, Talano, Julie A, additional, Curran, Kevin J., additional, Phillips, Christine L, additional, Karras, Nicole, additional, Fabrizio, Vanessa A., additional, Baumeister, Susanne H.C., additional, Cooper, Stacy, additional, Hermiston, Michelle, additional, Satwani, Prakash, additional, Macmillan, Margaret, additional, John, Samuel, additional, and Faramand, Rawan G, additional

Published
2024
Full Text
View/download PDF

13. Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Author

Shah, Nirali N., primary, Azzi, Jacques, additional, Cooper, Brenda, additional, Deol, Abhinav, additional, DiPersio, John F., additional, Koura, Divya, additional, Magenau, John, additional, McClune, Brian, additional, Muffly, Lori S, additional, Mushtaq, Muhammad Umair, additional, Narayan, Rupa, additional, Suh, Hyung C., additional, Nath, Sritama, additional, Whangbo, Jennifer, additional, and Koehne, Guenther, additional

Published
2024
Full Text
View/download PDF

14. Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Long Term Follow up of BMT CTN 1301 Progress II Trial

Author

Pasquini, Marcelo C., primary, Soiffer, Robert, additional, Logan, Brent, additional, Kaur, Manmeet, additional, Devine, Steven M., additional, Geller, Nancy, additional, Giralt, Sergio A., additional, Heslop, Helen E., additional, Horowitz, Mary M., additional, Litzow, Mark R., additional, Mendizabal, Adam, additional, Muffly, Lori S, additional, Nemecek, Eneida, additional, O'Donnell, Lynn C., additional, Schetelig, Johannes, additional, Shune, Leyla, additional, Solomon, Scott R., additional, Vasu, Sumithira, additional, Ho, Dr. Vincent T., additional, Perales, Miguel-Angel, additional, and Luznik, Leo, additional

Published
2024
Full Text
View/download PDF

15. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Author

O'Connor, Timothy E, primary, Lin, Chenyu, additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Faramand, Rawan G, additional, Kopmar, Noam E., additional, Dykes, Kaitlyn C, additional, Jeyakumar, Nikeshan, additional, Dekker, Simone E., additional, Gupta, Vishal, additional, Ahmed, Mohamed, additional, Logan, Aaron C., additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Tracy, Sean, additional, Kubiak, Michal, additional, Mukherjee, Akash, additional, Majhail, Navneet S., additional, Battiwalla, Minoo, additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Shaughnessy, Paul J., additional, Ladha, Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Solh, Melhem M, additional, Lee, Catherine J., additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Shah, Bijal D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Tsai, Dr. Stephanie B., additional, and Dholaria, Dr. Bhagirathbhai, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results